The Technical Analyst
Select Language :
immatics biotechnologies [IMTXW]

Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology

immatics biotechnologies Price, Forecast, Insider, Ratings, Fundamentals & Signals

immatics biotechnologies is listed at the NASDAQ Exchange

-16.92% $2.70

/ 28 mar 2024 @ 16:00


immatics biotechnologies: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 963.06 mill
EPS: 0
P/E: 0
Earnings Date: Jun 08, 2020
SharesOutstanding: 356.69 mill
Avg Daily Volume: 0 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Sell
Return On Asset: Neutral
DE: Neutral
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0 | sector: PE 0
PE RATIO: COMPANY / INDUSTRY
N/A
Company: PE 0 | industry: PE 0
DISCOUNTED CASH FLOW VALUE
$-6.74
(-349.55%) $-9.44
Date: 2024-03-29
Expected Trading Range (DAY)

$ 2.70 - 3.12

( +/- 7.35%)
ATR Model: 14 days

Forecast: 16:00 - $2.70

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
Volume Signals
Price $2.70 (-16.92% )
Volume 0.0031 mill
Avg. Vol. 0 mill
% of Avg. Vol 0 %

Today

Intraday chart data with high, low, open and close for immatics biotechnologies GmbH

Last 12 Months

Last 12 months chart data with high, low, open and close for immatics biotechnologies GmbH

RSI

Last 10 Buy & Sell Signals For IMTXW

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            immatics biotechnologies GmbH

IMTXW

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Last 10 Buy Signals

Date Signal @
SUPERUSDMar 29 - 09:34$1.359
UQCUSDMar 29 - 06:54$7.20
BNBUSDMar 29 - 09:31$615.19
TIMEUSDMar 29 - 09:3232.37
AGLDUSDMar 29 - 09:301.650
MINAUSDMar 29 - 09:29$1.238
CBKUSDMar 29 - 09:281.087
METAMar 28 - 16:00$485.58
MSTRMar 28 - 16:00$1 704.56
STORJUSDMar 29 - 09:26$0.817

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.